Resources

In this issue: Maintaining Donor Health and Safety: Review of Recently Published PPTA Donor Health Studies; Learn More About the 2023 Joachim Hilfenhaus Award Recipient, Thomas R. Kreil, Ph.D., Takeda; European Plasma Alliance Unveils Revamped Website and Logo; PPTA Members and Patient Groups Join to Advocate on Capitol Hill; Getting to Know the New Chair of the North America Board of Directors — Adam Grossman, ADMA Biologics, and more.

PDMPs — which are derived from human plasma from healthy donors — are essential for around 300,000 European patients who rely on these therapies to treat a variety of rare, chronic, and potentially life-threatening conditions, which are often genetic in origin. Without these treatments, many patients might not survive or would have a substantially diminished quality of life. In addition, plasma-derived medicines are also used in everyday treatment, such as supportive treatment in trauma cases, liver disease, cardiac surgery, and in some cases, pregnancy complications.